WEGOVY® FLEXTOUCH® 0.5mg (Italian)

WEGOVY® FLEXTOUCH 0.5mg (ITALIAN) – Key Features and Benefits

Wegovy® FlexTouch® 0.5mg is the second step in the dose escalation plan of semaglutide therapy for chronic weight management. It follows the 0.25mg starter dose and helps patients gradually adjust to the medication while minimizing side effects such as nausea.

• Active ingredient: Semaglutide

• Used in week 5–8 of dose escalation (after 0.25 mg)

• Supports weight loss, appetite suppression, and reduced food cravings

• Subcutaneous injection in pre-filled FlexTouch® pen (4 doses per pen)

• Mimics GLP-1 hormone to signal fullness and regulate appetite

• Backed by clinical data for sustained weight reduction and cardiovascular benefit

• Adolescent and adult use in patients meeting BMI and weight criteria

WEGOVY® FLEXTOUCH 0.5mg (ITALIAN) – Indications

The 0.5 mg strength is not a therapeutic dose but an intermediate step to help patients reach the effective maintenance dose (2.4 mg). It is used in both adult and adolescent populations as part of a controlled escalation protocol.

• Adults:

  • BMI ≥30 (obese) or 27–29.9 (overweight with comorbidities)

  • With heart disease and BMI ≥27 (even without diabetes)

• Adolescents (≥12 years, >60 kg):

  • With obesity

  • Continued use only if ≥5% BMI reduction after 12 weeks at 2.4 mg

• Used along with reduced-calorie diet and physical activity

• Not for type 1 diabetics or concurrent use with other weight loss products

WEGOVY® FLEXTOUCH 0.5mg (ITALIAN) – Ingredients

Each Wegovy® FlexTouch® 0.5 mg pen contains semaglutide and several excipients for stability. It is formulated as a clear, colorless injectable solution.

• Active ingredient:

  • Semaglutide: 1.34 mg/mL (2.0 mg semaglutide in 1.5 mL solution)

• Inactive ingredients:

  • Dibasic sodium phosphate dihydrate

  • Propylene glycol

  • Phenol

  • Water for injections

  • Sodium hydroxide/hydrochloric acid for pH balance

• Sodium-free: <23 mg sodium per dose

WEGOVY® FLEXTOUCH 0.5mg (ITALIAN) – How To Use

The 0.5 mg dose is taken once weekly during weeks 5 to 8 of treatment. It is part of a structured dose escalation to improve gastrointestinal tolerance before reaching the 2.4 mg maintenance dose.

• Injection route: Subcutaneous (abdomen, thigh, or upper arm)

• Frequency: Once per week, same day each week

• Dosing schedule:

  • Week 1–4: 0.25 mg

  • Week 5–8: 0.5 mg

  • Week 9–12: 1.0 mg

  • Week 13–16: 1.7 mg

  • Week 17+: 2.4 mg

• Administration tips:

  • Use FlexTouch® prefilled pen with NovoFine® needles

  • Any time of day, with or without food

  • If missed and ≤5 days late: take it ASAP; if >5 days: skip it

WEGOVY® FLEXTOUCH 0.5mg (ITALIAN) – Side Effects

Side effects are dose-dependent and may increase as the dose escalates. Most are gastrointestinal and usually improve with time. The 0.5 mg dose may still cause symptoms in sensitive individuals.

Common and less serious:

• Very common (≥1 in 10): Nausea, vomiting, diarrhea, constipation, abdominal pain, headache

• Common (≤1 in 10): Dizziness, flatulence, burping, bloating, indigestion, dry mouth, injection site reactions

• Uncommon (≤1 in 100): Fast heart rate, delayed stomach emptying, gallstones

Serious side effects:

• Pancreatitis: Severe abdominal pain radiating to the back

• Severe allergic reactions: Facial swelling, difficulty breathing, rash

• Bowel obstruction: Severe constipation, bloating, vomiting

• Hypoglycemia:

  • Especially in patients using insulin or sulfonylureas

  • Symptoms: cold sweat, shakiness, confusion, blurred vision

WEGOVY® FLEXTOUCH 0.5mg (ITALIAN) – Clinical Studies

The efficacy of Wegovy® was validated through multiple phase 3 clinical trials. While 0.5 mg is not the final therapeutic dose, it plays a critical role in dose escalation, allowing the body to adapt and avoid discontinuation due to side effects.

• Key results:

  • Sustained, clinically meaningful weight loss at maintenance dose

  • Lower incidence of side effects when following proper dose escalation

• Adolescents:

  • Require at least 5% BMI reduction after 12 weeks at 2.4 mg to continue

• Study features:

  • Weekly injection schedule

  • Diet and exercise required for best outcomes

  • Demonstrated cardiovascular benefit in non-diabetic patients

WEGOVY® FLEXTOUCH 0.5mg (ITALIAN) – Manufacturer Information

Wegovy® is developed and supplied by Novo Nordisk, a globally recognized leader in diabetes and obesity care. The company provides access to the WegovyCare® support program for Australian users.

• Manufacturer: Novo Nordisk A/S

• Australian distributor: Novo Nordisk Pharmaceuticals Pty. Ltd., Sydney

• New Zealand distributor: Novo Nordisk Pharmaceuticals Ltd., Auckland

• Product ID: Aust R 424391 (0.5 mg strength)

• Website: www.novonordisk.com.au

• Support: wegovycare.com.au (not TGA-authorized)

WEGOVY® FLEXTOUCH 0.5mg (ITALIAN) – FAQ

Is Wegovy® 0.5 mg effective on its own?
No, it is part of a dose escalation plan. Long-term results come from reaching the 2.4 mg dose.

What is the purpose of the 0.5 mg dose?
It helps your body adjust to semaglutide and reduces the likelihood of GI side effects as you move toward the target dose.

Can I stay on 0.5 mg if I feel fine?
No, staying on 0.5 mg long-term does not provide the full therapeutic effect. Always follow your doctor’s dosing plan.

Does Wegovy® 0.5 mg cause side effects?
Yes, common ones include nausea, diarrhea, and fatigue, but they tend to be less severe than those at higher doses.

What happens if I miss a 0.5 mg dose?
Inject within 5 days of the missed dose. If more than 5 days have passed, skip and resume on your regular schedule.

Can adolescents use 0.5 mg Wegovy®?
Yes, as part of the titration protocol—same schedule as adults if they meet eligibility criteria (≥12 years and >60 kg).